1
|
Gil-Raga M, Jantus-Lewintre E, Gallach S, Giner-Bosch V, Frangi-Caregnato A, Safont-Aguilera MJ, Garde-Noguera J, Zorraquino-Pina E, García-Martínez M, Camps-Herrero C. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clin Transl Oncol 2018; 20:1422-1429. [DOI: 10.1007/s12094-018-1874-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 04/01/2018] [Indexed: 12/13/2022]
|
2
|
Alcaide J, Delgado M, Legerén M, Jurado JM, Blancas I, Pereda T, López J, Garrido M, Sánchez MJ, García JL, Rueda A. Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncol Lett 2016; 12:3127-3134. [PMID: 27899972 PMCID: PMC5103908 DOI: 10.3892/ol.2016.5068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2015] [Accepted: 06/27/2016] [Indexed: 12/27/2022] Open
Abstract
Aflibercept is a recombinant fusion protein that acts by inhibiting tumoural angiogenesis. Efficacy data obtained in the VELOUR randomised study has contributed to the approval of aflibercept as a second-line metastatic colorectal cancer (mCRC) treatment following an oxaliplatin-based regimen. The present study reports a case series of five patients with mCRC, who were treated in two centres since 2011 in the Compassionate Use Program for aflibercept. All patients had a KRAS mutation and previously received palliative fluoropyrimidine-oxaliplatin-based chemotherapy with bevacizumab. A doublet with irinotecan combined with aflibercept was administered until progression of disease. The majority of patients received a greater number of aflibercept cycles than the median reported in the VELOUR study (12 vs. 7 cycles), with manageable and reversible toxicity. The most frequent adverse events observed were diarrhoea, neutropenia, fatigue, proteinuria and hypertension. Most cases obtained a progression-free survival greater than the median reported in the VELOUR study (11 vs. 6.9 months) and, in a subgroup of patients previously treated with bevacizumab, and a median survival time of ~47 months was reached from the initial treatment of the disease. The present study contrasts the efficacy and safety results obtained from the pivotal VELOUR trial, and confirms that aflibercept, used in routine clinical practice outside of the clinical trial environment, is active and well-tolerated following bevacizumab treatment.
Collapse
Affiliation(s)
- Julia Alcaide
- Oncology Department, Costa del Sol Hospital, Marbella, 29603 Málaga, Spain
| | - Mayte Delgado
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - Marta Legerén
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - José Miguel Jurado
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - Isabel Blancas
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - Teresa Pereda
- Pathology Department, Costa del Sol Hospital, Marbella, 29603 Málaga, Spain
| | - Jorge López
- Pathology Department, Costa del Sol Hospital, Marbella, 29603 Málaga, Spain
| | - Margarita Garrido
- Pharmacy and Nutrition Department, Costa del Sol Hospital, Marbella, 29603 Málaga, Spain
| | - María J Sánchez
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - José L García
- Oncology Department, San Cecilio Clinical Hospital, Granada, 18014 Andalucía, Spain
| | - Antonio Rueda
- Oncology Department, Costa del Sol Hospital, Marbella, 29603 Málaga, Spain
| |
Collapse
|